

FRED HUTCH · UNIVERSITY OF WASHINGTON · SEATTLE CHILDREN'

FUNDS AVAILABLE FOR NEW INVESTIGATORS

Open to Cancer Consortium Members
April 2025

RELEASE DATE: APRIL 1, 2025

APPLICATIONS DUE: MAY 16, 2025 BY 5:00PM PST

Funds are available from the Cancer Center Support Grant (CCSG) to provide developmental support to new or junior faculty who are establishing their research within the Cancer Consortium. These funds provide a flexible source of funding designed to allow new investigators to work toward obtaining future, independent research funding. Departments are also eligible to apply for this funding to support new faculty being hired by a Consortium institution.

Two to three New Investigator Awards of up to \$100,000 direct costs each (plus F&A/indirect costs) will be made from Consortium funds. All proposed research must be cancer-focused and may include projects aligned with Cancer Consortium strategic priorities (see appendix to learn more about priority areas). Financial need will be taken into consideration for those who did not receive substantial research funds as part of their negotiated start-up package.

ELIGIBILITY

To apply for this funding opportunity, all applicants must be:

- Cancer Consortium members or eligible to become members at the time of award. Membership criteria and application are available on the Consortium website.
- Assistant Professor-level or higher and who have begun their appointment at one of the Consortium institutions (Fred Hutch, University of Washington, Seattle Children's) on or after July 2022.
- New faculty being recruited who will meet Consortium membership criteria at the time of the award start date (July 1, 2025).

Applicants who meet any of the following criteria are **not eligible** to apply for this award:

- Consortium members in acting faculty positions and faculty with affiliate Consortium membership.
- Faculty who have received:
 - A CCSG-funded award of any kind since June 2022.
 - A pilot award funded by Safeway or the Hite Foundation since June 2022.
- Investigators who are principal investigators on R01, P01, or P50 grants are considered to already have independent research funding, so therefore they are not eligible for this funding mechanism.

ALLOWABLE COSTS

Funds can be used to support any aspect of an investigator's research except for their own or other faculty salaries, training and tuition, and capital equipment. Allowable costs include support staff salaries (such as a research coordinator or lab technician), supplies, travel, publishing, regulatory costs, shared resources usage, etc. **A budget and budget justification are required for all applications.** Funds should be expended within two years of the award start date.

APPLICATION

All application elements will be completed within <u>InfoReady</u>, the Fred Hutch's centralized database for external, internal, and limited applicant award opportunities. This information is provided below for reference as you complete the application in the InfoReady platform. Please adhere to NIH font and line spacing guidelines as outlined <u>here</u>.

1. Requirements

- Project Title (Last Name, New Investigator Award)
- Primary Institution
- Primary Institution Start Date (Month, Year)
- Amount that you received in research funds as part of your start-up package

2. Statement of Interest

In one page, the applicant should provide a statement of interest to include the following:

- Describe 1-2 specific aims of their research (350-400 words). This can be current work or an
 extension of an ongoing project. No preliminary data is needed; the purpose of these awards is to
 help investigators gather preliminary data needed to seek outside funding. Please also describe how
 the preliminary data generated will help support future grant applications and what funding
 mechanisms may be pursued.
- Show how any proposed collaboration reveals the creative strengths of the investigator and increases transdisciplinary research within the Cancer Consortium.
- Describe how this work will benefit cancer prevention, diagnosis, treatment, or survivorship.
- If relevant, describe how this project addresses the Cancer Consortium's strategic priorities (please refer to the *Appendix* on pages 4-5).

3. Budget & Budget Justification

Please use the template provided on the Supporting Documents page in the InfoReady platform.

Primary Site Fred Hutch

- Hutch Grants routing will be required only after an award is made.
- UW or Children's collaborators are allowable and a subaward should be budgeted.
 - Submit a PHS398 budget page for each institution. Direct cost budgets should total \$100,000 combined.
 - An LOI from the subaward institution must accompany the pilot application.
- If a subaward will go to a non-Consortium institution, the subaward institution's F&A must be included in the FH direct cost total.

Primary Site UW or Children's

- Institutional sign-off should be received prior to submission of a pilot award proposal for review.
- An LOI must accompany the pilot application.
- Per UW OSP, submit an e-GC1 anticipating that if awarded, both direct and indirect costs will be received.
- If a subaward will go to a non-Consortium institution, the subaward institution's F&A must be included in the UW or SC direct cost total.

4. NIH Biosketch

The applicant should provide an NIH Biosketch that adheres to the most recent NIH guidelines. A biosketch sample, template, and instructions can be found here. Please be sure all information is current, especially the applicant's appointment date at their primary Consortium institution.

5. Other Support

The applicant should provide an NIH Other Support document adhering to the most recent NIH guidelines. Other Support sample, template, and instructions can be found here. Please be sure all information is current.

6. Institutional Sign-off

• Fred Hutch Applicants

Institutional sign-off is not required at the time of submission for applicants from Fred Hutch who intend to keep the entire budget at Fred Hutch. Fred Hutch OSR approval via Hutch Grants will be required at the time of award. However, if the applicant anticipates issuing a subaward for a portion of the budget to UW or Children's, an LOI from the institution receiving the subaward will need to be included in the application packet.

- UW and Seattle Children's Applicants
 Per Executive Order 34, institutional sign-off by the applicant's Office of Sponsored
 Research/Programs is required at the time of application. A signed letter of intent must be submitted with the application packet.
 - **UW Applicants:** please complete the FDP Subrecipient LOI_UW supporting document found in InfoReady and upload where indicated (PDF only)
 - **SC Applicants:** please complete the Fred Hutch LOI_Seattle Children's supporting document found in InfoReady and upload where indicated (PDF only)


SUBMISSION DEADLINE

Applications are due **Friday**, **May 16 by 5:00pm PST**. Applications received after this deadline will not be accepted for evaluation by the 2024 New Investigator Award Review Committee.

SUBMISSION INSTRUCTIONS

Applications will be submitted in InfoReady, the Fred Hutch's centralized database for external, internal, and limited applicant award opportunities: https://fredhutch.infoready4.com/#freeformCompetitionDetail/1969709. Log-in instructions are provided below.

Fred Hutch Applicants. Please log in with your Fred Hutch Cancer Center username and password. **University of Washington and Seattle Children's Applicants.** Please create an account by selecting "Register" as shown below. <u>Please use the applicant's primary institutional affiliation email address.</u> If you would like an administrator to submit on your behalf, the primary applicant will need to sign-in and designate this role.



If you have any questions about this award competition or using the InfoReady platform, please reach out to cancerconsortium@fredhutch.org.

APPENDIX

Catchment Area

The Consortium's catchment area:

- Constitutes all 39 counties in Washington.
- Includes a population of 7,656,200 (2020 data).
- Is comprised of 33% racial/ethnic minority populations.
- From 2017-2021, the age-adjusted incidence rate for all cancer cases combined in WA was 439.7 per 100,000 (95% CI 437.7-441.7).



<u>Populations experiencing health</u> disparities in cancer

- Black/African American
- American Indian/Alaska Native
- Children ages 0-14 with Leukemia
- Women ages ≥65 with Ovarian Cancer

Priority Cancers


- Breast cancer
- Colon cancer
- Lung cancer
- Hematologic malignancies
- Prostate cancer

Cancer Control Priorities

- Colorectal cancer screening
- Breast cancer screening
- HPV vaccination

Below is a snapshot of the cancer burden in Washington from 2015-2019, as presented in *A Report to the Community: 2023 Community Health Needs Assessment*.

- American Indian/Alaska Native (Indigenous) populations had the highest cancer incidence rate (513.9 per 100,000) of any racially or ethnically defined group.
 - Indigenous people in WA experience significantly higher incidence rates of female breast, lung, colorectal, hematologic, liver, bladder, thyroid, and oral cancers compared to Indigenous people in the US.
- Non-Hispanic Black populations had the highest cancer mortality rate (158.2 per 100,000) of any racially or ethnically defined group.
 - Non-Hispanic Blacks have significantly higher mortality rates for prostate cancer compared to non-Hispanic whites.
- Liver cancer is the 3rd and 5th most common cause of cancer death for the Asian/Pacific Islander and Hispanic populations in WA, respectively.



Among children ages 0 through 14 years of age in Washington:

- the top 5 most common cancers are: hematologic malignancies, brain, soft tissue, kidney, and other endocrine cancers.
- the top 3 causes of cancer death are: hematologic malignancies, brain & other nervous system, and other endocrine cancers.

Among adolescents and young adults ages 15 through 39 years of age in Washington:

- the top 5 most common cancers are: female breast, testis, thyroid, hematologic malignancies and invasive melanoma.
- the top 5 causes of cancer death are: female breast, hematologic malignancies, brain & other nervous system, colorectal, and cervix.

For more information, please see <u>A Report to the Community: 2023 Community Health Needs Assessment</u>. If you need any other cancer data for your application, please contact the Office of Community Outreach & Engagement at enddisparities@fredhutch.org.